IDEXX Adds Mast Cell Tumor Test to Cancer Dx Panel and Cuts Imaging Radiation by 25%
IDEXX will add canine mast cell tumor detection to its Cancer Dx Panel in North America by mid-2026, covering over one-third of dog cancers with 2–3-day turnaround at no extra cost. It also launched the ImageVue DR50 Plus system, cutting radiation dose by up to 25% versus its DR50 model and integrating AI-powered workflows.
1. Expansion of IDEXX Cancer Dx Panel to Include Canine Mast Cell Tumors
IDEXX Laboratories will add mast cell tumor detection to its Cancer Dx Panel in mid-2026 at no extra cost to veterinary customers in the United States and Canada. The panel, currently deployed in over 5,500 practices across North America for lymphoma detection, will now address more than one-third of all canine cancer cases by screening at-risk dogs (those aged seven years and older, or high-risk breeds aged four and above) during routine wellness visits. Results will be delivered within 2–3 days in the U.S. (2–4 days in Canada) using the same specimen requirements and workflow, leveraging a test proven to detect lymphoma up to eight months before clinical signs appear.
2. Rollout of IDEXX inVue Dx™ FNA Cytology for Rapid In-Clinic Diagnosis
As of late Q4 2025, IDEXX began a controlled rollout of FNA cytology on its inVue Dx Cellular Analyzer, enabling veterinarians to evaluate skin masses and identify cellular profiles while pet owners wait. The slide-free design allows instant expert review requests from IDEXX pathologists without slide preparation. This capability will initially focus on mast cell tumors in dogs and is slated to expand to additional tumor types over time, helping practices reduce turnaround times and improve case throughput in high-volume clinics.
3. Launch of ImageVue DR50 Plus Digital Imaging System
IDEXX introduced the ImageVue DR50 Plus system in Q4 2025, delivering high-definition radiographs at up to 25% lower radiation dose versus the prior ImageVue DR50 model and up to 60% lower dose compared to competing veterinary systems. The new 17" x 17" detector option expands anatomical coverage beyond the existing 14" x 17" panel. Integrated AI-powered image optimization and automated positioning protocols reduce retakes, while seamless connectivity with IDEXX Web PACS™ and Telemedicine Consultants (160+ board-certified specialists) cuts case-submission clicks by over 45%, accelerating diagnostic workflows in over 75% of U.S. clinics that perform radiography.
4. Strategic and Financial Impact for Investors
These diagnostic innovations position IDEXX to drive recurring revenue growth through expanded test volumes and hardware sales. The Cancer Dx Panel’s mast cell tumor addition and in-clinic cytology rollout can boost annual reference laboratory volumes by an estimated 10%, while the ImageVue DR50 Plus upgrade cycle may increase imaging system revenue by 15% in 2026. With approximately 11,000 employees serving customers in over 175 countries and membership in the S&P 500 Index, IDEXX continues to leverage its global scale and R&D investments to strengthen margins and support long-term shareholder value.